These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2904759)

  • 1. Implications of doxazosin therapy on risk of coronary heart disease.
    Hansson L
    Am Heart J; 1988 Dec; 116(6 Pt 2):1832-7. PubMed ID: 2904759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
    Taylor SH
    Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
    Mazzola C; Guerrasio E
    Am Heart J; 1988 Dec; 116(6 Pt 2):1797-801. PubMed ID: 2904753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1763-6. PubMed ID: 2904747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
    Talseth T; Westlie L; Daae L; Vatle S
    Am Heart J; 1988 Dec; 116(6 Pt 2):1790-6. PubMed ID: 2904752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with doxazosin in general medical practice.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1748-57. PubMed ID: 2904745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
    Castrignano R; D'Angelo A; Pati T; Al Awady M; Tronca R; Crepaldi G
    Am Heart J; 1988 Dec; 116(6 Pt 2):1778-84. PubMed ID: 2904750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
    Pool JL; Taylor AA; Nelson EB
    Am J Med; 1989 Aug; 87(2A):57S-61S. PubMed ID: 2569825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardiovascular effects of alpha-receptor blocking agents.
    Leren P
    J Hypertens Suppl; 1992 Jun; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
    Giorgi G; Legramante JM; Fioravanti G; Paies G; Legramante A
    Am Heart J; 1988 Dec; 116(6 Pt 2):1801-5. PubMed ID: 2904754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.
    Bartels AC; de Vries PM; Oe LP; van Bronswÿk H; Donker AJ; Réveillaud RJ; Fillastre JP; Zech P
    Am Heart J; 1988 Dec; 116(6 Pt 2):1772-7. PubMed ID: 2904749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
    Nechwatal W; Berger J; Blumrich W; Bouzo H; Brandl K; Braun S; Laukaitis A; Müller G; Ryba W; Schreiegg J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1806-14. PubMed ID: 2904755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
    Frick MH; Cox DA; Himanen P; Huttunen M; Pitkäjärvi T; Pörsti P; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
    Am J Cardiol; 1987 May; 59(14):61G-67G. PubMed ID: 2884854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma.
    Miura Y; Yoshinaga K
    Am Heart J; 1988 Dec; 116(6 Pt 2):1785-9. PubMed ID: 2904751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.
    Lindner UK; von Manteuffel GE; Stafunsky M
    Am Heart J; 1988 Dec; 116(6 Pt 2):1814-20. PubMed ID: 2904756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
    Englert RG; Mauersberger H
    Am Heart J; 1988 Dec; 116(6 Pt 2):1826-32. PubMed ID: 2904758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice.
    van den Hogen AL
    Am Heart J; 1988 Dec; 116(6 Pt 2):1757-62. PubMed ID: 2904746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden.
    Lindgren B
    Am Heart J; 1990 Mar; 119(3 Pt 2):748-53. PubMed ID: 1968701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha 1-antagonists in the treatment of hypertension.
    Grimm RH
    Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.